First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety-Reference-Cited by-同舟云学术

First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety

Published:2024-11 Issue:11 Volume:42 Page:374.e21-374.e29
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Yanagisawa Takafumi^ORCID,Mori Keiichiro,Kawada Tatsushi,Katayama Satoshi,Uchimoto Taizo,Tsujino Takuya,Nishimura Kazuki,Adachi Takahiro,Toyoda Shingo,Nukaya Takuhisa,Fukuokaya Wataru,Urabe Fumihiko,Murakami Masaya,Yamanoi Tomoaki,Bekku Kensuke,Komura Kazumasa,Takahara Kiyoshi,Hashimoto Takeshi,Fujita Kazutoshi,Azuma Haruhito,Ohno Yoshio,Shiroki Ryoichi,Uemura Hirotsugu,Araki Motoo,Kimura Takahiro

Publisher

Elsevier BV

Reference37 articles.

1. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the international metastatic renal cell carcinoma database consortium risk group in patients with advanced renal cell carcinoma;Haanen;ESMO Open,2023

2. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

3. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial;Motzer;Lancet Oncol,2022

4. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial;Motzer;Lancet Oncol,2019

5. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426;Plimack;J Clin Oncol,2023